**DEPARTMENT OF HEALTH & HUMAN SERVICES**

Public Health Service

Food and Drug Administration
Rockville, MD 20857

NDA 20-718/S-028

Schering Corporation
Attention: Deborah Urquhart, Ph.D.
Director, Global Regulatory Affairs
2000 Galloping Hill Road
Kenilworth, NJ 07033

Dear Dr. Urquhart:

Please refer to your supplemental new drug application dated April 27, 2007, submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act for Integrilin (eptifibatide) Injection.

We acknowledge receipt of your submissions dated September 19, 2007 and November 26, 2008.

This supplemental new drug application provides for changes to the package insert as requested by the Agency in our November 28, 2006 and March 23, 2007 letters. In these letters we requested that you make the following revisions to the **CLINICAL TRIALS** section of the label:

**(b) (4)**

**(b) (4)**



**(b) (4)**

Also, you requested the following change in the **DESCRIPTION** section:

> "Integrilin (eptifibatide) Injection is a clear, colorless, sterile, non-pyrogenic solution for intravenous (IV) use."

To read:

> "Integrilin (eptifibatide) Injection is a clear, colorless, sterile, non-pyrogenic solution for intravenous (IV) use with an empirical formula of $C_{35}H_{49}N_{11}O_9S_2$ and a molecular weight of 831.96."

In the September 19, 2007 submission, you proposed the following change to the **CLINICAL TRIALS** section replacing those requested by the Division above:

**(b) (4)**

You also proposed adding the following paragraph to the ESPRIT trial description:

After further discussion, you amended this labeling supplement on November 26, 2008, and proposed the following changes to the **CLINICAL TRIALS** section of the label:

> An analysis of the results by sex suggests that women who would not routinely be expected to undergo percutaneous coronary intervention (PCI) receive less benefit from eptifibatide (95% confidence limits for relative risk of 0.94 to 1.28) than do men (0.72 to 0.90). This difference may be a true treatment difference, the effect of other differences in these subgroups, or a statistical anomaly. No differential outcomes were seen between male and female patients undergoing PCI (see results for ESPRIT).

Under **CLINICAL STUDIES,** after the first paragraph under Table 5, you added a paragraph that reads:

> There was no treatment difference with respect to sex in ESPRIT. Eptifibatide reduced the incidence of the primary endpoint in both men (95% confidence limits for relative risk: 0.54, 1.07) and women (0.24, 0.72) at 48 hours.

You changed the fourth paragraph under the **HOW SUPPLIED** section from:

> "* USP controlled Room Temperature: 25°C (77°F) with excursions permitted between 15-30°C (59-86°F)."

To read:

> "Store at 25°C (77°F); excursions permitted to 15°-30°C (59°—86°F) [see USP Controlled Room Temperature]."

You also proposed the following minor editorial change:

> At the end of the **INDICATIONS AND USAGE** section, "(see **CLINICAL STUDIES**)" replaced "as described in **CLINICAL TRIALS**."

We have completed our review of this supplemental new drug application, as amended. It is approved, effective on the date of this letter, for use as recommended in the final printed labeling (FPL) submitted on November 26, 2008.

Please submit the FPL electronically according to the guidance for industry entitled, "Providing Regulatory Submissions in Electronic Format – NDA."

If you issue a letter communicating important information about this drug product (*i.e.*, a "Dear Health Care Professional" letter), we request that you submit a copy of the letter to this NDA and a copy to the following address:

MEDWATCH
Food and Drug Administration
5515 Security Lane
HFD-001, Suite 5100
Rockville, MD 20852

We remind you that you must comply with the requirements for an approved NDA set forth under 21 CFR 314.80 and 314.81.

If you have any questions, please call:

Alison Blaus
Regulatory Health Project Manager
(301) 796 -1138

Sincerely,

*{See appended electronic signature page}*

Norman Stockbridge, M.D., Ph.D.
Director
Division of Cardiovascular and Renal Products
Office of Drug Evaluation I
Center for Drug Evaluation and Research

Attached:
Agreed-upon labeling text

---

**This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.**

---

/s/

---

Norman Stockbridge

12/15/2008 05:11:01 PM